ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

{"_buckets": {"deposit": "b1904815-1618-4148-9114-c86967539cc7"}, "_deposit": {"id": "23848", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "23848"}, "status": "published"}, "_oai": {"id": "oai:nagoya.repo.nii.ac.jp:00023848", "sets": ["501"]}, "author_link": ["70774", "70775", "70776", "70777", "70778", "70779", "70780", "70781", "70782", "70783", "70784", "70785", "70786", "70787", "70788", "70789", "70790", "70791"], "item_10_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2017-02", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "2", "bibliographicPageEnd": "553", "bibliographicPageStart": "546", "bibliographicVolumeNumber": "24", "bibliographic_titles": [{"bibliographic_title": "Annals of Surgical Oncology", "bibliographic_titleLang": "en"}]}]}, "item_10_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Background: Advantages of neoadjuvant chemotherapy combined with monoclonal antibodies for treating patients with resectable colorectal cancer liver metastasis (CLM) have not been established. The purpose of this study was to evaluate the efficacy and safety of oxaliplatin-based regimen (FOLFOX or XELOX) plus monoclonal antibodies (cetuximab or bevacizumab) treatment in patients with resectable CLM. Methods: A single-arm, open-label, multicenter, phase II trial was conducted for patients aged ≥ 20 years with resectable and untreated CLM. Patients received preoperative FOLFOX (6 cycles) or XELOX (4 cycles). Cetuximab or bevacizumab was administered to patients with wild-type or mutated KRAS codons 12 and 13, respectively. The primary endpoint was progression-free survival (PFS). Results: Between January 2010 and June 2012, 47 patients were enrolled from 12 institutions. Wild-type or mutant KRAS sequences were examined in 32 and 15 patients, respectively. Twenty-one (45 %) patients experienced Grades 3/4 adverse events, and 55 % of all patients responded to therapy. The sizes of tumors of patients in the wild-type KRAS group were significantly reduced compared with those of the mutant KRAS group. The overall rates of liver resection and postoperative morbidity were 83 and 14 %, respectively, and the median PFS was 15.6 months. The median PFS times of the KRAS wild-type and mutant groups were 22.5 months and 10.5 months, respectively. Conclusions: Neoadjuvant therapy using FOLFOX/XELOX combined with monoclonal antibodies did not improve PFS, although it was administered safely and had less adverse effects after liver resection.", "subitem_description_language": "en", "subitem_description_type": "Abstract"}]}, "item_10_identifier_60": {"attribute_name": "URI", "attribute_value_mlt": [{"subitem_identifier_type": "DOI", "subitem_identifier_uri": "http://doi.org/10.1245/s10434-016-5557-9"}, {"subitem_identifier_type": "HDL", "subitem_identifier_uri": "http://hdl.handle.net/2237/26028"}]}, "item_10_publisher_32": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Springer", "subitem_publisher_language": "en"}]}, "item_10_relation_11": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://doi.org/10.1245/s10434-016-5557-9", "subitem_relation_type_select": "DOI"}}]}, "item_10_rights_12": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "The final publication is available at Springer via http://doi.org/10.1245/s10434-016-5557-9", "subitem_rights_language": "en"}]}, "item_10_select_15": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "author"}]}, "item_10_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1068-9265", "subitem_source_identifier_type": "PISSN"}]}, "item_1615787544753": {"attribute_name": "出版タイプ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_ab4af688f83e57aa", "subitem_version_type": "AM"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "open access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_abf2"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Kataoka, Masato", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "70774", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kanda, Mitsuro", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "70775", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ishigure, Kiyoshi", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "70776", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Matsuoka, Hiroshi", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "70777", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Sato, Yusuke", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "70778", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Takahashi, Takao", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "70779", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tanaka, Chihiro", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "70780", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Deguchi, Tomohiro", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "70781", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Shibata, Yoshihisa", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "70782", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Sato, Mikinori", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "70783", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Inagaki, Hitoshi", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "70784", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Matsui, Takanori", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "70785", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kondo, Akinori", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "70786", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Takano, Nao", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "70787", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tanaka, Haruyoshi", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "70788", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Sakamoto, Junichi", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "70789", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Oba, Koji", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "70790", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kondo, Ken", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "70791", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2018-02-01"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "The_COMET_Open-label_PhaseII_Study.pdf", "filesize": [{"value": "682.4 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_note", "mimetype": "application/pdf", "size": 682400.0, "url": {"label": "The_COMET_Open-label_PhaseII_Study.pdf ファイル公開:2018/02/01", "objectType": "fulltext", "url": "https://nagoya.repo.nii.ac.jp/record/23848/files/The_COMET_Open-label_PhaseII_Study.pdf"}, "version_id": "49c29ffd-9c74-4001-b380-5eec3ad97486"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "The COMET Open-label Phase II Study of Neoadjuvant FOLFOX or XELOX Treatment Combined with Molecular Targeting Monoclonal Antibodies in Patients with Resectable Liver Metastasis of Colorectal Cancer", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "The COMET Open-label Phase II Study of Neoadjuvant FOLFOX or XELOX Treatment Combined with Molecular Targeting Monoclonal Antibodies in Patients with Resectable Liver Metastasis of Colorectal Cancer", "subitem_title_language": "en"}]}, "item_type_id": "10", "owner": "1", "path": ["501"], "permalink_uri": "http://hdl.handle.net/2237/26028", "pubdate": {"attribute_name": "PubDate", "attribute_value": "2017-04-19"}, "publish_date": "2017-04-19", "publish_status": "0", "recid": "23848", "relation": {}, "relation_version_is_last": true, "title": ["The COMET Open-label Phase II Study of Neoadjuvant FOLFOX or XELOX Treatment Combined with Molecular Targeting Monoclonal Antibodies in Patients with Resectable Liver Metastasis of Colorectal Cancer"], "weko_shared_id": -1}
  1. C100 医学部/医学系研究科
  2. C100a 雑誌掲載論文
  3. 学術雑誌

The COMET Open-label Phase II Study of Neoadjuvant FOLFOX or XELOX Treatment Combined with Molecular Targeting Monoclonal Antibodies in Patients with Resectable Liver Metastasis of Colorectal Cancer

http://hdl.handle.net/2237/26028
http://hdl.handle.net/2237/26028
679b6657-b2c2-4c9c-92cc-0f5b2436d8b3
名前 / ファイル ライセンス アクション
The_COMET_Open-label_PhaseII_Study.pdf The_COMET_Open-label_PhaseII_Study.pdf ファイル公開:2018/02/01 (682.4 kB)
Item type 学術雑誌論文 / Journal Article(1)
公開日 2017-04-19
タイトル
タイトル The COMET Open-label Phase II Study of Neoadjuvant FOLFOX or XELOX Treatment Combined with Molecular Targeting Monoclonal Antibodies in Patients with Resectable Liver Metastasis of Colorectal Cancer
言語 en
著者 Kataoka, Masato

× Kataoka, Masato

WEKO 70774

en Kataoka, Masato

Search repository
Kanda, Mitsuro

× Kanda, Mitsuro

WEKO 70775

en Kanda, Mitsuro

Search repository
Ishigure, Kiyoshi

× Ishigure, Kiyoshi

WEKO 70776

en Ishigure, Kiyoshi

Search repository
Matsuoka, Hiroshi

× Matsuoka, Hiroshi

WEKO 70777

en Matsuoka, Hiroshi

Search repository
Sato, Yusuke

× Sato, Yusuke

WEKO 70778

en Sato, Yusuke

Search repository
Takahashi, Takao

× Takahashi, Takao

WEKO 70779

en Takahashi, Takao

Search repository
Tanaka, Chihiro

× Tanaka, Chihiro

WEKO 70780

en Tanaka, Chihiro

Search repository
Deguchi, Tomohiro

× Deguchi, Tomohiro

WEKO 70781

en Deguchi, Tomohiro

Search repository
Shibata, Yoshihisa

× Shibata, Yoshihisa

WEKO 70782

en Shibata, Yoshihisa

Search repository
Sato, Mikinori

× Sato, Mikinori

WEKO 70783

en Sato, Mikinori

Search repository
Inagaki, Hitoshi

× Inagaki, Hitoshi

WEKO 70784

en Inagaki, Hitoshi

Search repository
Matsui, Takanori

× Matsui, Takanori

WEKO 70785

en Matsui, Takanori

Search repository
Kondo, Akinori

× Kondo, Akinori

WEKO 70786

en Kondo, Akinori

Search repository
Takano, Nao

× Takano, Nao

WEKO 70787

en Takano, Nao

Search repository
Tanaka, Haruyoshi

× Tanaka, Haruyoshi

WEKO 70788

en Tanaka, Haruyoshi

Search repository
Sakamoto, Junichi

× Sakamoto, Junichi

WEKO 70789

en Sakamoto, Junichi

Search repository
Oba, Koji

× Oba, Koji

WEKO 70790

en Oba, Koji

Search repository
Kondo, Ken

× Kondo, Ken

WEKO 70791

en Kondo, Ken

Search repository
アクセス権
アクセス権 open access
アクセス権URI http://purl.org/coar/access_right/c_abf2
権利
言語 en
権利情報 The final publication is available at Springer via http://doi.org/10.1245/s10434-016-5557-9
抄録
内容記述 Background: Advantages of neoadjuvant chemotherapy combined with monoclonal antibodies for treating patients with resectable colorectal cancer liver metastasis (CLM) have not been established. The purpose of this study was to evaluate the efficacy and safety of oxaliplatin-based regimen (FOLFOX or XELOX) plus monoclonal antibodies (cetuximab or bevacizumab) treatment in patients with resectable CLM. Methods: A single-arm, open-label, multicenter, phase II trial was conducted for patients aged ≥ 20 years with resectable and untreated CLM. Patients received preoperative FOLFOX (6 cycles) or XELOX (4 cycles). Cetuximab or bevacizumab was administered to patients with wild-type or mutated KRAS codons 12 and 13, respectively. The primary endpoint was progression-free survival (PFS). Results: Between January 2010 and June 2012, 47 patients were enrolled from 12 institutions. Wild-type or mutant KRAS sequences were examined in 32 and 15 patients, respectively. Twenty-one (45 %) patients experienced Grades 3/4 adverse events, and 55 % of all patients responded to therapy. The sizes of tumors of patients in the wild-type KRAS group were significantly reduced compared with those of the mutant KRAS group. The overall rates of liver resection and postoperative morbidity were 83 and 14 %, respectively, and the median PFS was 15.6 months. The median PFS times of the KRAS wild-type and mutant groups were 22.5 months and 10.5 months, respectively. Conclusions: Neoadjuvant therapy using FOLFOX/XELOX combined with monoclonal antibodies did not improve PFS, although it was administered safely and had less adverse effects after liver resection.
言語 en
内容記述タイプ Abstract
出版者
言語 en
出版者 Springer
言語
言語 eng
資源タイプ
資源タイプresource http://purl.org/coar/resource_type/c_6501
タイプ journal article
出版タイプ
出版タイプ AM
出版タイプResource http://purl.org/coar/version/c_ab4af688f83e57aa
DOI
関連タイプ isVersionOf
識別子タイプ DOI
関連識別子 https://doi.org/10.1245/s10434-016-5557-9
ISSN
収録物識別子タイプ PISSN
収録物識別子 1068-9265
書誌情報 en : Annals of Surgical Oncology

巻 24, 号 2, p. 546-553, 発行日 2017-02
著者版フラグ
値 author
URI
識別子 http://doi.org/10.1245/s10434-016-5557-9
識別子タイプ DOI
URI
識別子 http://hdl.handle.net/2237/26028
識別子タイプ HDL
戻る
0
views
See details
Views

Versions

Ver.1 2021-03-01 14:22:53.196828
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3